Loading clinical trials...
Loading clinical trials...
A Phase 3, 16-week, Randomized, Double-Blind, Placebo-Controlled, Parallel- Group Study to Assess the Impact of Lebrikizumab on Vaccine Responses in Adult Patients With Moderate-to-Severe Atopic Dermatitis
Conditions
Interventions
Lebrikizumab
Placebo
Locations
85
United States
Clinical Research Center of Alabama- Birmingham
Birmingham, Alabama, United States
Burke Pharmaceutical Research
Hot Springs, Arkansas, United States
Arkansas Research Trials
North Little Rock, Arkansas, United States
Orange County Research Institute
Anaheim, California, United States
Wallace Medical Group, Inc.
Beverly Hills, California, United States
First OC Dermatology
Fountain Valley, California, United States
Start Date
November 17, 2020
Primary Completion Date
August 3, 2022
Completion Date
September 30, 2022
Last Updated
October 17, 2023
NCT06461897
NCT07262983
NCT06389136
NCT06342713
NCT07223697
NCT07290803
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions